PreventionGenetics→Exact Sciences
Acquisition · Cash · EXAS · announced Jan 9, 2022
Announced
Jan 9, 2022
Closed
Jan 9, 2022
Economics
Cash()
Pre-deal · pre-deal mark: 2022, year precision · Exact Sciences press release — PreventionGenetics acquisition, 2022
~$190M (Laboratory Economics reporting)
Target
PreventionGenetics
Diagnostics · Diagnostic / genomic
HQ Marshfield, WI · Founded 2004
CLIA-certified genetic testing laboratory — 5,000+ predefined tests for hereditary cancer (BRCA1/2, Lynch syndrome), carrier screening, and whole exome/genome sequencing
- PR Newswire — Exact Sciences press release (Jan 9, 2022)
- SEC EDGAR — Exact Sciences 8-K (Jan 10, 2022)
- Laboratory Economics — deal reporting (Jan 15, 2022)
Acquirer
Exact Sciences (EXAS)
Precision Medicine
HQ Madison, WI
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
5,000+ genetic tests for hereditary cancer (BRCA1/2, Lynch syndrome) + carrier screening — enters hereditary cancer testing market; leverages Exact Sciences' 300K+ provider relationships in primary care and women's health
Evidence ladder
Secondary (press / IR)
PR Newswire — Exact Sciences press release (Jan 9, 2022)
Primary (regulatory / filing)
SEC EDGAR 8-K (Jan 10, 2022)
SEC EDGAR filings (ticker locator)
Limitations
- ~$190M (Laboratory Economics reporting)
- Pre-deal valuation sourced from: Exact Sciences press release — PreventionGenetics acquisition, 2022. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Gateway Genomics | Myriad Genetics | Nov 1, 2022 | same evidence class |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Thrive Earlier Detection | Exact Sciences | Oct 27, 2020 | ||
| Igenomix | Vitrolife | Jul 8, 2021 |
Other verified deals by Exact Sciences
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Genomic Health | Exact Sciences | Jul 29, 2019 | Precision Medicine |
Patient empowerment context
Empowerment context — PreventionGenetics
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Not recommended genetic testing (NCCN: almost all should)37%cited HLTH 2022
Other curated mappings on these gaps: Biotheranostics, Endomagnetics, Genomic Health, Foundation Medicine
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.